A phase IIb study of CBM-CD20.1 in patients with advanced Non-Hodgkin Lymphoma

Trial Profile

A phase IIb study of CBM-CD20.1 in patients with advanced Non-Hodgkin Lymphoma

Planning
Phase of Trial: Phase II

Latest Information Update: 05 Nov 2015

At a glance

  • Drugs Anti-CD20-CAR-transduced T cells (Primary)
  • Indications Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 05 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top